Manufacturer:
Teva
Route of Administration:
Subcutaneous
Site of Care:
Outpatient
Website:
Approved Indication:
for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia in adult and pediatric patients 1 month and older
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
Therapeutic Area:
- Oncology